Nuklearmedizin 1986; 25(05): 188-193
DOI: 10.1055/s-0038-1624340
Originalarbeiten - Original Articles
Schattauer GmbH

Comparison in Rabbits of Chole-Scintigraphic Properties of Several 99mTc-IDA Derivatives

J. Kapuscinski
*   From the Departments of Nuclear Medicine, Medical Academy of Lodz, Poland
,
J. Liniecki
*   From the Departments of Nuclear Medicine, Medical Academy of Lodz, Poland
,
K. Durski
*   From the Departments of Nuclear Medicine, Medical Academy of Lodz, Poland
,
Mikiciuk-Olasik Elzbieta
**   From the Departments of Chemical Technology of Drugs, Medical Academy of Lodz, Poland
› Author Affiliations
Further Information

Publication History

Received: 25 April 1986

Publication Date:
12 January 2018 (online)

Pathways and kinetics of excretion were compared to four 99mTc-IDA derivatives in healthy rabbits of both sexes. Assessment of differences between the compounds was based upon: plasma clearance, characteristics of time-activity curves measured scintigraphically over the liver (time of the peak Tmax; time for decline of activity to half the peak value - T50%), and hepatocytic mean transit time (MTT) as derived after deconvolution of the hepatic time-activity curve. Hepatocyte transit time was short and similar to 99mTc-complexes of Mebrofenin, 2,4-diethyl IDA (HEPIDA) and 3-iodo-2,6- diethylphenylcarbamoylmethyliminodiacetic acid (JODIDA); it was evidently longer for 99mTc-p-butyl-IDA (BIDA). 99mTc-HEPIDA displayed significant urinary elimination; the remaining three compounds were excreted practically completely via the biliary route. It is concluded that optimal parameters were displayed by 99mTc-Mebrofenin and 99mTc-JODIDA.

Zusammenfassung

Die Wege und Kinetik der Ausscheidung von vier 99mTc-IDA-Derivaten wurden an gesunden Kaninchen beiden Geschlechts untersucht. Die ermittelten Unterschiede zwischen den untersuchten Verbindungen basierten auf der Plasmaclearance und der Charakteristik von Zeitaktivitätskurven, die szintigraphisch über der Leber und dem Herzen erfaßt wurden. Aus der Leberkurve ergab sich die Zeit, in der das Aktivitätsmaximum erreicht wurde (Tmax) und die Zeit bis zum Abfall auf die Hälfte des Maximums (T50%). Die mittlere hepatozytäre Transitzeit (MTT) wurde aus beiden Zeitaktivitätskurven nach Dekonvolution abgeleitet. Die MTT war kurz und ähnlich für die 99mTc-Komplexe mit Mebrofenin, HEPIDA und JODIDA. Sie war ungefähr zweimal so lang für 99mTc-pbutyl- IDA, BIDA. 99mTc-HEPIDA wurde in signifikanten Mengen über die Harnwege ausgeschieden im Gegensatz zu den anderen untersuch- ten Verbindungen, die praktisch ausschließlich über die Leber und Gallenwege eliminiert wurden. Vom diagnostischen Standpunkt aus wurden optimale Eigenschaften für 99mTc- Mebrofenin und 99mTc-JODIDA ermittelt.

 
  • REFERENCES

  • 1 Bendat J. S., Piersal A. G.. Random data: Analysis and Measurement Procedures. Wiley and Sons; New York: 1971
  • 2 Burns H. D., Sowa D. T., Marzilli L. G.. Improved synthesis of N-/2,6- dimethylphenylcarbamoylmethyl/iminodiacetic acid and analogs. J. Pharm. Sei 1978; 67: 1434-6.
  • 3 Fritzberg A. R., Klingensmith III W. C.. Quest for the perfect hepatobiliary radiopharmaceutical. J. nucl. Med 1982; 23: 543-6.
  • 4 Harwey E. B., Loberg M. D., Cooper M. 99mTc-HIDA: A new radiopharmaceutical for hepatobiliary imaging. J. nucl. Med 1975; 16: 533.
  • 5 Hernandez H, Rosenthal L. A cross-over study comparing the kinetics of 99mTc-labeled diisopropyl and p-butyl IDA analogs in patients. Can. clin. nucl. Med 1980; 5/4: 159-65.
  • 6 Klingensmith W CIII, Fritzberg A. R., Koep L. J.. Comparison of 99mTcdiethyl- iminodiacetic acid and 131I rose bengal for hepatobiliary studies in livertransplant patients. J. nucl. Med 1979; 20: 314-8.
  • 7 Klingensmith W CIII, Fritzberg A. R., Spitzer V. M.. et al. Clinical comparison of 99mTc-diethyl IDA and 99mTc-PIPIDA for evaluation of the hepatobiliary system. Radiology 1980; 134: 195-9.
  • 8 Klingensmith W CIII, Fritzberg A. R., Spitzer V. M.. et al. Clinical comparison of diisopropyl-IDA 99mTc and diethyl-IDA 99mTc for evaluation of the hepatobiliary system. Radiology 1981; 140: 791-5.
  • 9 Klingensmith W CIII, Fritzberg A. R., Spitzer V. M.. et al. Clinical evaluation of 99mTc trimethylbromo-IDA and 99mTc diisopropyl-IDA for hepatobiliary imaging. Radiology 1983; 146: 181-4.
  • 10 Lathi B. P.. Communication Systems. Wiley and Sons; New York: 1968
  • 11 Nunn A. D., Loberg M. D., Conley R. A.. et al. The development of a new cholescintygraphic agent. Tc-SQ 26, 962 using a structure distribution relationship approach. J. nucl. Med 1981; 22: 51.
  • 12 Nunn A. D., Loberg M. D., Conley R. A.. A structure distribution relationship approach leading to the development of 99mTc mebrofenin: An improved cholescintigraphic agent. J. nucl. Med 1983; 24: 423-30.
  • 13 Otnes R. K., Enockson L. Digital Time Series Analysis. Wiley and Sons; New York: 1972
  • 14 Ryan J, Cooper M, Loberg M, Hervey E, Sikroski S. Technetium-99mlabeled N-(2,6-dimethylphenylcarbamoylmethyl/ iminodiacetic acid [99mTc-HIDA]): A new radiopharmaceutical for hepatobiliary imaging studies. J. nucl. Med 1977; 18: 995-1002.
  • 15 Studniarek M, Durski K, Liniecki J. Plasma clearance of 99mTc-N(2,4-dimethyl- acetanilido)iminodiacetate complex as a measure of parenchymal liver damage. Nucl. Med 1983; 22: 140-4.
  • 16 Studniarek M, Liniecki J, Kapuscinski J, Durski K, Brykalski D. Comparative evaluation of diagnostic features of 99mTc-HEPIDA and 99mTc-BIDA. Pol. Przegl. Rad. Med. Nukl. (in press).
  • 17 Taavitsainen M, Korhola O, Riihimäki E, Tallroth K. Technetium- 99m-diethyl-IDA cholescintigraphy in differential diagnostics of jaundice. Scand. J. Gastroenterol 1979; 14: 567-75.
  • 18 Taavitsainen M, Riihimäki E, Tähti E. Body disappearance and liver mean transit time of WmTc-diethyl-IDA. Eur. J. nucl. Med 1980; 05: 147-50.
  • 19 Wistow B. W., Subramanian G, Van Heertum R. L.. et al. An evaluation of 99mTc-labeled hepatobiliary agents. J. nucl. Med 1977; 18: 455-61.
  • 20 Cholescintigraphy in Severly Jaundiced Patients: SOLCO NUCLEAR advertising material for JODIDA. SOLCO NUCLEAR Radiopharmaceutical Division of Soles Basle Ltd.;